Vortioxetine (Trintellix) for Depression
Vortioxetine (Trintellix) for Depression
November 25, 2013 (Issue: 1430)
The FDA has approved vortioxetine (vor" tye ox' e teen;
Trintellix – Takeda/Lundbeck), a new serotonergic drug,
for treatment of major depressive disorder. Like vilazodone
(Viibryd), another serotonergic antidepressant,
it has been claimed to...more
1. Vilazodone (Viibryd) – a new antidepressant. Med Lett Drugs Ther 2011; 53:53.
2. N Henigsberg et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012; 73:953.
3. E Alvarez et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15:589.
4. R Jain et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013; 16:313.
5. AR Mahableshwarkar et al. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013; 29:217.
6. C Katona et al. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27:215.
7. JP Boulenger et al. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26:1408.
8. DS Baldwin et al. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28:1717.
9. EL Theunissen et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93:493.
10. G Chen et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013; 33:727.
11. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
12. Approximate wholesale acquisition cost (WAC) for all tablet strengths. Source: Analy$ource® Monthly (Selected from FDB MedKnowledge™) November 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail price may be higher.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Vortioxetine (Trintellix) for Depression
Article code: 1430b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
